Healthcare Industry News: Mazor Robotics
News Release - January 2, 2014
Mazor Robotics Announces Two Renaissance Systems orders in the U.S. and International MarketsSeven New Renaissance Systems Ordered in the 2013 Fourth Quarter; Enters 2014 with Install Base of 63 Systems
CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics Ltd. (TASE: MZOR; NASDAQCM: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today orders of two Renaissance systems in late December, ending the 2013 fourth quarter with a total of seven system sales. In the U.S., the system was ordered by Littleton Adventist Hospital (Littleton, CO) and the second system was ordered internationally by Bestech, the Company’s distributor in Israel, for installation in a hospital in Haifa, Israel.
Bestech, the Company’s distribution partner in Israel, has installed the Renaissance system at Bnai Zion Medical Center, located in Haifa, Israel. Established in 1922 as the first Jewish hospital in Haifa, Bnai Zion Medical Center focuses on rehabilitation activities, offering orthopedic rehabilitation, neurological rehabilitation, cardio rehabilitation, physical therapy and occupational therapy.
“Our momentum, both in the U.S. and internationally, and the purchase of these Renaissance systems demonstrates the continued support and interest which surgeons and hospital administrators express toward our technology,” commented Ori Hadomi, Chief Executive Officer. “We expect these hospitals to experience positive clinical and business benefits, similar to the other hospitals.”
Mazor Robotics (TASE: MZOR; NASDAQCM: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the clinical and economic benefits of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC), including those discussed under the heading "Risk Factors" in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
Source: Mazor Robotics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.